Aspire Biopharma
ASBP
57 hedge funds and large institutions have $268M invested in Aspire Biopharma in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
2% more funds holding
Funds holding: 56 → 57 (+1)
1% more capital invested
Capital invested by funds: $267M → $268M (+$1.35M)
0% less ownership
Funds ownership: 0.08% → 0.07% (-0%)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$8.54M |
| 2 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$7.36M |
| 3 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$6.13M |
| 4 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$4.03M |
| 5 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$3.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$14.4M |
| 2 |
Millennium Management
New York
|
-$6.5M |
| 3 |
TCA
Taconic Capital Advisors
New York
|
-$6.19M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$3.05M |
| 5 |
SC
Sculptor Capital
New York
|
-$2.63M |
ASBP Hedge Fund Activity: Q1 2023 in Review
57 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q1 2023, worth a combined $268M — up 0.51% from $267M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ASBP positions and 7 closed out — a net gain of 2 holders — while 10 added to existing stakes and 11 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $8.54M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $14.4M sold.
- 57 institutional investors held Aspire Biopharma (ASBP) as of Q1 2023, up from 56 in Q4 2022.
- Funds reported $268M of Aspire Biopharma stock for Q1 2023, up 0.51% quarter-over-quarter.
- 9 funds opened new Aspire Biopharma positions in Q1 2023 and 7 closed out, a net change of +2 holders.
- The largest Aspire Biopharma buyer in Q1 2023 was D.E. Shaw & Co, an estimated $8.54M added.
- The largest Aspire Biopharma seller in Q1 2023 was Highbridge Capital Management, an estimated $14.4M sold.
Based on aggregated 13F filings for Q1 2023.